CSIMarket Company Name, Ticker, Competitors, else..
 
Voyager Therapeutics Inc   (NASDAQ: VYGR)
Other Ticker:  
 
 
Price: $3.9100 $0.03 0.773%
Day's High: $3.9598 Week Perf: 0.64 %
Day's Low: $ 3.85 30 Day Perf: -7.35 %
Volume (M): 215 52 Wk High: $ 10.66
Volume (M$): $ 839 52 Wk Avg: $6.80
Open: $3.90 52 Wk Low: $3.56



 Market Capitalization (Millions $) 225
 Shares Outstanding (Millions) 58
 Employees 46
 Revenues (TTM) (Millions $) 80
 Net Income (TTM) (Millions $) -65
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 4

Voyager Therapeutics Inc
Voyager Therapeutics Inc is a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases. The company aims to use gene therapy to deliver potentially transformative treatments directly to the affected areas of the brain. Voyager Therapeutics is developing therapies for diseases such as Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS). The company's approach involves using adeno-associated virus (AAV) vectors to deliver therapeutic genes to specific brain regions. Voyager Therapeutics is conducting clinical trials to evaluate the safety and efficacy of its gene therapies, with the goal of providing new treatment options for patients suffering from these devastating diseases.


   Company Address: 75 Hayden Avenue Lexington 2421 MA
   Company Phone Number: 259-5340   Stock Exchange / Ticker: NASDAQ VYGR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA   -1.14%    
CRSP        4.03% 
KRYS        3.15% 
RGNX        11.54% 
RXRX        6.26% 
SGMO        2.82% 
• View Complete Report
   



Product Service News

Voyager Therapeutics Advances Tau Silencing Gene Therapy Candidate for Alzheimers Disease

Published Wed, Nov 20 2024 12:00 PM UTC

Voyager Therapeutics, a prominent company in the field of gene therapy, has announced the selection of VY1706 as their lead candidate for a promising tau silencing gene therapy aimed at treating Alzheimer s disease. This decision marks a significant step forward in addressing one of the most challenging and prevalent neurodegenerative conditions impacting millions of individ...
Partnership

Voyager Therapeutics Strengthening Gene Therapy Portfolio Amid Enhanced Financial Performance,

Published Thu, Sep 5 2024 12:00 PM UTC

Voyager Therapeutics, Inc. has made significant strides in recent months, underscoring its commitment to advancing gene therapy through strategic partnerships and notable financial improvements. This article delves into Voyager s recent licensing agreement for next-generation capsids and examines the company?s return on average invested assets (ROI) as reported in its second...
Stock Market Announcement

Voyager Therapeutics Pioneers Employment Agreement with New Hires, Impacts Shareholders,

Published Thu, Aug 29 2024 8:01 PM UTC


Voyager Therapeutics Enters into Employment Agreement with New Hires, Impacting Shareholders
LEXINGTON, Mass., Aug. 29, 2024 - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a pioneering biotechnology company focused on advancing neurogenetic medicines, has recently signed an employment agreement with a newly hired employee. This agreement includes the granting of a no...
Voyager Therapeutics Inc

Voyager Therapeutics Inc. Soars in Q2 2024: Transformative Growth in Revenue and Profitability!



Voyager Therapeutics Inc, a biotechnology company specializing in neurogenetic medicines, has recently released its financial results for the interval ending June 30, 2024. These results showcase a significant reduction in losses per share, improvement in earnings per share, and a remarkable increase in revenue. Additionally, exciting developments in the company's research and upcoming participation in a prestigious conference indicate a positive outlook for Voyager Therapeutics. This article will delve into the implications of these facts and speculate on their impact on the company's future.
Improved Financial Performance:
Voyager Therapeutics Inc has demonstrated noteworthy progress in its financial performance compared to the previous year. The company managed to decrease the loss per share from $-0.51 to $-0.18, indicating a positive trajectory. Moreover, the earnings per share improved from $-0.20 to an undisclosed positive value, signifying an overall enhanced profitability.
Clinical Study

LEXINGTON, Mass., May 16, 2024 - In the relentless pursuit of innovative neurogenetic treatments, Voyager Therapeutics, Inc. (Nasdaq: VYGR) has crossed a significant milestone. The company proudly announced today that the first participants have been dosed in a groundbreaking Phase 1a single ascending dose (SAD) trial of VY-TAU01. Developed as an investigational anti-tau antibody, ...

Published Thu, May 16 2024 11:00 AM UTC

Reversing the Tide of Alzheimer s: Voyager Therapeutics Initiates Promising Phase 1a Trial with VY-TAU01, a Novel Anti-Tau AntibodyLEXINGTON, Mass., May 16, 2024 - In the relentless pursuit of innovative neurogenetic treatments, Voyager Therapeutics, Inc. (Nasdaq: VYGR) has crossed a significant milestone. The company proudly announced today that the first participants have ...






Voyager Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com